Lila Hope

Cooley advised Zai Lab on its exclusive collaboration and license agreement with Blueprint Medicines for the development and commercialization of BLU-945 and BLU-701 for the treatment of patients with epidermal growth factor receptor (EGFR) -driven non-small cell lung cancer (NSCLC) in Greater China, including mainland China, Hong Kong, Macau and Taiwan. 
 
Under the terms of the agreement, Blueprint Medicines will receive an upfront cash payment of $25 million and will be eligible to receive up to $590 million in potential development, regulatory and sales-based milestone payments, and tiered royalties on a product-by-product basis ranging from the low-teens to mid-teens on annual net sales of BLU-945 and BLU-701 in Greater China, subject to adjustment in specified circumstances. In addition, Zai Lab will be responsible for all the development costs for BLU-945 and BLU-701 occurring in Greater China and will receive the rights to develop and exclusively commercialize BLU-945 and BLU-701 in the region.
 
Lawyers Lila Hope and Jennifer Raab led the Cooley team advising Zai Lab.

Cooley advised I-Mab on its global collaboration agreement with AbbVie for the development and commercialization of lemzoparlimab, one of I-Mab’s leading drug candidates, for the treatment of multiple cancers. Lawyers Lila Hope and Jennifer Raab led the Cooley team advising I-Mab on the agreement. 

Cooley advised CardioKinetix on its $50 million financing led by Edwards Lifesciences. CardioKinetix also entered into an agreement with Edwards Lifesciences that provides the company with the right to acquire CardioKinetix based on future regulatory milestones.

CardioKinetix is a medical device company pioneering a catheter-based treatment for heart failure.

San Francisco – Cooley advised Adamas Pharmaceuticals on its initial public offering. Adamas, a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system, now trades on the Nasdaq Global Stock Market under the symbol "ADMS."

Thus far in 2014, Cooley has advised on 43 completed public offerings, including 22 completed IPOs.

Cooley advised the underwriters on Ascendis Pharma's $124.2 million initial public offering. Ascendis Pharma is a clinical-stage biopharmaceutical company applying its TransCon technology to develop a pipeline of therapies to address significant unmet medical needs. The company now trades on the Nasdaq Global Market under the symbol "ASND."

Merrill Lynch, Pierce, Fenner & Smith and Leerink Partners acted as the joint book-running managers, and Wells Fargo Securities acted as co-manager for the offering.